molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
Company profile
Ticker
MTEM
Exchange
Website
CEO
Eric Poma
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
THRESHOLD PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Molecular Templates OpCo, Inc. • THLD Enterprises (UK), Limited ...
IRS number
943409596
MTEM stock data
Latest filings (excl ownership)
S-3
Shelf registration
25 Apr 24
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
8-K
Cost Associated with Exit or Disposal Activities
12 Apr 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
29 Mar 24
8-K
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
28 Mar 24
8-K
Termination of a Material Definitive Agreement
15 Mar 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
13 Nov 23
Latest ownership filings
4
BIOTECH AG BB
4 Apr 24
4
KEVIN M. LALANDE
4 Apr 24
SC 13D/A
SANTE HEALTH VENTURES I LP
2 Apr 24
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
4
Maurizio Voi
25 Jan 24
4
Jason S. Kim
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.81 mm | 15.81 mm | 15.81 mm | 15.81 mm | 15.81 mm | 15.81 mm |
Cash burn (monthly) | (no burn) | 538.83 k | 1.71 mm | 2.26 mm | 2.51 mm | 4.58 mm |
Cash used (since last report) | n/a | 3.72 mm | 11.83 mm | 15.61 mm | 17.35 mm | 31.64 mm |
Cash remaining | n/a | 12.09 mm | 3.98 mm | 201.95 k | -1.54 mm | -15.83 mm |
Runway (months of cash) | n/a | 22.4 | 2.3 | 0.1 | -0.6 | -3.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 11.41 bn |
Total shares | 60.69 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BLVGF Bellevue | 11.23 mm | $5.39 bn |
BBBOF BB Biotech | 11.19 mm | $0.00 |
Sante Health Ventures I | 7.04 mm | $91.96 mm |
K2 HealthVentures Equity Trust | 6.25 mm | $3.31 mm |
Biotechnology Value Fund L P | 5.25 mm | $0.00 |
BVF | 5.00 mm | $2.40 bn |
Longitude Capital Partners III | 4.65 mm | $0.00 |
TAK Takeda Pharmaceutical | 2.31 mm | $15.07 mm |
Vanguard | 2.21 mm | $1.06 bn |
Caxton | 2.05 mm | $985.44 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Lalande Kevin M. | Common Stock | Grant | Acquire A | Yes | No | 2.35 | 175,000 | 411.25 k | 175,000 |
2 Apr 24 | Lalande Kevin M. | Warrants Common Stock | Grant | Acquire A | Yes | No | 0.125 | 1,154,154 | 144.27 k | 1,154,154 |
2 Apr 24 | Lalande Kevin M. | Pre-Funded Warrants Common Stock | Grant | Acquire A | Yes | No | 2.349 | 402,077 | 944.48 k | 402,077 |
2 Apr 24 | Biotech Target | Common Stock | Buy | Acquire P | No | No | 2.35 | 250,000 | 587.50 k | 1,279,820 |
2 Apr 24 | Biotech Target | Common Warrants Common Stock | Buy | Acquire P | No | No | 0.125 | 769,334 | 96.17 k | 769,334 |
2 Apr 24 | Biotech Target | Prefunded Warrants Common Stock | Buy | Acquire P | No | No | 2.349 | 134,667 | 316.33 k | 134,667 |
23 Jan 24 | Eric E Poma | Stock Option Common Stock | Grant | Acquire A | No | No | 3.55 | 23,333 | 82.83 k | 23,333 |
23 Jan 24 | Jason S. Kim | Stock Option Common Stock | Grant | Acquire A | No | No | 3.55 | 10,000 | 35.50 k | 10,000 |
23 Jan 24 | Maurizio Voi | Stock Option Common Stock | Grant | Acquire A | No | No | 3.55 | 10,000 | 35.50 k | 10,000 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Apr 24
What's Going On With Molecular Templates Stock?
9 Apr 24
Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual Meeting
9 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Press releases
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
9 Apr 24
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
29 Mar 24
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
28 Mar 24
Molecular Templates, Inc. Provides Interim Update
4 Mar 24
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
8 Feb 24